tert-butyl 4-[(4-bromophenyl)-(5,6-difluoro-1H-benzimidazol-2-yl)methylidene]piperidine-1-carboxylate | 846049-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: tert-butyl 4-[(4-bromophenyl)-(5,6-difluoro-1H-benzimidazol-2-yl)methylidene]piperidine-1-carboxylate
• CAS: 846049-61-4
• 化学式: C₂₄H₂₄BrF₂N₃O₂
• 分子量: 504.374
• InChiKey: VCDZKXPDAOJRNX-UHFFFAOYSA-N

物化性质

• 沸点：
  635.3±65.0 °C(Predicted)
• 密度：
  1.444±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[(4-bromophenyl)-(5,6-difluoro-1H-benzimidazol-2-yl)methylidene]piperidine-1-carboxylate 在 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 生成 4''-[(1-cyclopropylmethyl-piperidin-4-ylidene)-(5,6-difluoro-1H-benzoimidazol-2-yl)-methyl]-biphenyl-3-carbonitrile
  参考文献：
  名称：

  Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists

  摘要：

  Biaryl urea lead compound 1 was discovered earlier in our MCH antagonist program. Novel benzimidazole analogues with increased chemical stability, devoid of the potential carcinogenic liability associated with a biarylamine moiety, were synthesized and evaluated to be potent MCH R1 antagonists. Two compounds in this series have demonstrated in vivo efficacy in a rodent obesity model. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.062
• 作为产物：
  描述：

  1-BOC-4-(4-溴苯甲酰)哌啶 在 吡啶 、 正丁基锂 、 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl 4-[(4-bromophenyl)-(5,6-difluoro-1H-benzimidazol-2-yl)methylidene]piperidine-1-carboxylate
  参考文献：
  名称：

  Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists

  摘要：

  Biaryl urea lead compound 1 was discovered earlier in our MCH antagonist program. Novel benzimidazole analogues with increased chemical stability, devoid of the potential carcinogenic liability associated with a biarylamine moiety, were synthesized and evaluated to be potent MCH R1 antagonists. Two compounds in this series have demonstrated in vivo efficacy in a rodent obesity model. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.062

文献信息

• US7214691B2
  申请人：——

  公开号：US7214691B2

  公开（公告）日：2007-05-08